The U.S. Food and Drug Administration (FDA) recently approved a new prescription pain reliever for adults with moderate to severe acute pain. The drug—branded as Journavx®—is the first in a new class of pain meds that will soon be available nationwide.
“This is really exciting news because for the first time in more than 20 years, we’re developing a brand-new class of analgesics,” says Dr. Jason Smith, MD, an interventional pain physiatrist at Atlantic Health.
How does it work?
Dr. Smith explains this groundbreaking non-opioid medication does not affect the brain’s reward center the way opioids do. Instead, it targets selective pain pathways, blocking the sodium channels that stimulate pain.
What conditions does it treat?
This oral medication is currently FDA-approved solely for short-term pain management use. This includes postsurgical pain, trauma, and acute back pain or osteoarthritic injuries, depending on the severity.
Are there side effects?
Although some patients experience side effects, studies show most responses to Journavx® are relatively mild. Adverse reactions can include itching, rash, or muscle spasms, and may be more severe in patients who are sensitive to these issues.
Three existing classes of prescription pain relievers
- Prescription-strength Tylenol® (acetaminophen) disrupts pain signals in the body, making it effective for mild to moderate pain. It lower fevers and relieves aches and pains. However, acetaminophen does not reduce inflammation in the body.
- Non-steroid anti-inflammatory drugs (NSAIDs) treat mild to moderate pain by blocking certain enzymes (Cox-1 and Cox-2) and producing prostaglandins that decrease pain, inflammation, and swelling.
- Opioids act on the brain’s reward centers. Although opioids are strong and effective, they come with a significant risk of addiction, which has fueled an epidemic of dependency and overdose.
“I describe the three classes of pain medications like a radio station,” says Dr. Smith. “Tylenol® turns down the volume. NSAIDS stop the broadcast altogether. Opioids block the broadcast and play music – songs you want to hear again and again.”
Ushering in a new class of pain relievers
According to Dr. Smith, opioids will always be an effective way to treat short-term pain. What’s needed is a safe long-term way to treat moderate to severe pain. This promising new drug class just might be the answer.
“For now, this new medication is being marketed for severe acute pain,” says Dr. Smith. “But at some point, I wouldn't be surprised if it’s extended to manage long-term pain, too. It’s got a lot of potential.”
Is it time to talk to your doctor?
Despite the drug’s limited availability and insurance coverage, Dr. Smith encourages patients to talk with their doctors about pain management options.
“Patients are already hearing about Journavx® and asking questions,” he says. “It’s important to talk with your health care provider about new advancements in health care.”
Related articles
